Skip to main content


Media Coverage

FTC Patent License Rule Sure To Annoy Drugmakers

7 November 2013
Litigation & Dispute Resolution partner Chris Kelly (Palo Alto) is quoted in an article discussing that attorneys believe that the US Federal Trade Commission's newly finalized rule requiring pharmaceutical companies to report more exclusive patent licenses for antitrust approval under the Hart-Scott-Rodino Act will increase costs and delays for the industry.
The Build a Report feature requires the use of cookies to function properly. Cookies are small text files that are placed on your computer by websites that you visit. They are widely used in order to make websites work, or work more efficiently. If you do not accept cookies, this function will not work. For more information please see our Privacy Policy

You have no pages selected. Please select pages to email then resubmit.